Abstract | BACKGROUND: CASE REPORTS: We herein report the cases of 2 HL patients after alloHSCT who both responded well to the therapy; however, 1 patient developed chronic GVHD (cGVHD) within 3 days of administration of nivolumab. This patient already had a history of cGVHD and interestingly showed manifestations at the very same sites. The other patient never showed any signs of cGVHD, even with the administration of 13 cycles of anti-PD-1 therapy and large doses of donor lymphocytes. CONCLUSION: The rapid reappearance of cGVHD after blockade of PD-1 implies an important role of PD-1/PD-L1 in peripheral immune tolerance in cGVHD after alloHSCT and warrants further investigation.
|
Authors | Sebastian Klobuch, Daniela Weber, Barbara Holler, Wolfgang Herr, Ernst Holler, Daniel Wolff |
Journal | Oncology research and treatment
(Oncol Res Treat)
Vol. 40
Issue 7-8
Pg. 447-450
( 2017)
ISSN: 2296-5262 [Electronic] Switzerland |
PMID | 28683452
(Publication Type: Case Reports, Journal Article)
|
Copyright | © 2017 S. Karger GmbH, Freiburg. |
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- B7-H1 Antigen
- CD274 protein, human
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- Nivolumab
|
Topics |
- Adult
- Allografts
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- B7-H1 Antigen
(metabolism)
- Chronic Disease
- Combined Modality Therapy
- Female
- Graft vs Host Disease
(chemically induced, immunology)
- Hematopoietic Stem Cell Transplantation
- Hodgkin Disease
(drug therapy, immunology)
- Humans
- Immune Tolerance
(drug effects, immunology)
- Nivolumab
- Programmed Cell Death 1 Receptor
(metabolism)
- Recurrence
|